Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. completed the acquisition of a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd.
July 14, 2022
Share
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities (Shanghai) Asset Management Co.,Ltd. signed a share transfer agreement to acquire a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd. for approximately CNY 340 million on June 17, 2022. Zhongtai Asset Management will pay CNY 6.63 cash per share for 51,374,735 shares of Shanxi Zhendong Pharmaceutical Co. As a part of consideration, the first installment will be paid within 5 working days and the remaining of CNY 272.491594 million will be paid after 18 months. The transaction needs to be reviewed and confirmed by the Shenzhen Stock Exchange before it can go through the relevant procedures for the transfer of shares by agreement at the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited.
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities (Shanghai) Asset Management Co.,Ltd. completed the acquisition of a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd. on July 15, 2022.
Shanxi Zhendong Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs, chemical raw materials and preparations. The Company's main products include anti-tumor series, cardiovascular and cerebrovascular series, anti-infection series, digestive system series, vitamin nutrition series, respiratory system series, antipyretic analgesic series and nervous system series. The Company is also involved in the cultivation of medicinal herbs, as well as the wholesale and retail of pharmaceutical products. The Company distributes its products in domestic market, with North China market as its main market.
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. completed the acquisition of a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd.